PainChek LtdASX: PCK

PainChek has productive final FDA De Novo clearance meeting

· Issued by PainChek Ltd

Filed with ASX · · 3 pages · English

Summary by 6ix AI

PainChek Ltd has announced a productive meeting with the FDA regarding its De Novo regulatory clearance process for its pain assessment application. The meeting addressed final questions related to recent clinical trial results and established a revised timeline for submission and decision. PainChek is compiling additional information to align with FDA feedback, aiming for submission by the end of June. The FDA has committed to a decision within a specified timeframe after receiving the final submission, potentially allowing for market entry later this year.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

PainChek Ltd on 6ix

Story so far

Earlier from PainChek

Later from PainChek

All PainChek news releases